SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented at the American Urological Association (AUA) 2023 Annual Meeting validate the real-world ...
Objective The Patient-Oriented Prostate Utility Scale (PORPUS) is a combined profile and utility-based quality of life measure for prostate cancer patients. Our objectives were to adapt the PORPUS ...
Genomic alterations and their pathologic responses in high-risk localized prostate cancer (HRLPC) in subprotocol 1 of the Genomic Umbrella Neoadjuvant study (GUNS). Hazard ratios (HRs) and 95% ...
Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
View post: Winter Storm Warning Issued for 36 Inches of Snow, Wind Chills Below Zero on New Year’s Day If a person has an “aggressive” prostate cancer with a Gleason score of 9, what does that mean?
For more than 80 years, men have been told that testosterone fuels prostate cancer. But a more nuanced picture has emerged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback